Novo Nordisk A/S (NONOF)
OTCMKTS
· Delayed Price · Currency is USD
112.70
+0.70 (0.63%)
Oct 30, 2024, 11:08 AM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 68.06B DKK in the quarter ending June 30, 2024, with 25.34% growth. This brings the company's revenue in the last twelve months to 258.00B, up 28.15% year-over-year. In the year 2023, Novo Nordisk had annual revenue of 232.26B with 31.26% growth.
Revenue (ttm)
258.00B DKK
Revenue Growth
+28.15%
P/S Ratio
n/a
Revenue / Employee
4.01M DKK
Employees
64,319
Market Cap
497.77B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sandoz Group AG | 10.11B |
| Telix Pharmaceuticals Limited | 430.80M |
| Elekta AB (publ) | 1.69B |
| Ryman Healthcare Limited | 411.39M |
| Verano Holdings Corp. | 920.97M |
| Vireo Growth Inc. | 98.04M |
| Medexus Pharmaceuticals Inc. | 108.78M |
Novo Nordisk News
- 15 hours ago - Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says - CNBC
- 19 hours ago - US FDA says lowest dose of Novo Nordisk's weight-loss drug now available - Reuters
- 23 hours ago - Eli Lilly stock tumbles 10% after missing estimates and slashing profit guidance - CNBC
- 2 days ago - Novo Nordisk A/S - share repurchase programme - GlobeNewsWire
- 2 days ago - Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates - Business Wire
- 3 days ago - Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution? - The Motley Fool
- 4 days ago - This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic) - The Motley Fool
- 6 days ago - Ozempic Can Potentially Cut Risk Of Alzheimer's Compared To Other Diabetic Medicines, Study Shows - Benzinga